Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. BAX
BAX logo

BAX Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
16.725
Open
16.080
VWAP
16.41
Vol
4.34M
Mkt Cap
8.16B
Low
15.900
Amount
71.18M
EV/EBITDA(TTM)
9.28
Total Shares
516.25M
EV
15.64B
EV/OCF(TTM)
16.45
P/S(TTM)
0.72
Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.
Show More

Events Timeline

(ET)
2026-03-30
08:40:00
Baxter International Launches IV Verify System to Enhance Nursing Efficiency
select
2026-03-16 (ET)
2026-03-16
09:00:00
Baxter Reiterates FY26 Revenue Outlook Flat to Up 1%
select
2026-03-16
09:00:00
Baxter CFO Joel Grade Departs, Anita Zielinski Named Interim CFO
select
2026-02-12 (ET)
2026-02-12
16:20:00
Dow Jones Falls 669.42 Points, Nasdaq Drops 469.32 Points
select

News

Newsfilter
5.0
03-30Newsfilter
Baxter Launches IV Verify Line Labeling System to Enhance Patient Safety
  • System Innovation: Baxter introduced the IV Verify Line Labeling System at the 2026 American Organization for Nursing Leadership Conference, offering an automated alternative to traditional handwritten labels, aimed at enhancing medication management safety and efficiency while helping clinicians save time and reduce the likelihood of medication errors.
  • Clinical Efficiency Boost: The IV Verify system allows clinicians to scan medication barcodes and instantly print three-part adhesive labels, saving an average of one to two minutes per IV setup, time that can be redirected to patient interactions, thereby improving the quality of care.
  • Patient Safety Assurance: Implementation of the system has significantly increased IV labeling compliance in hospitals and reduced the incidence of central line-associated bloodstream infections (CLABSI) when used as part of a prevention bundle, highlighting its importance in high-risk environments.
  • Broad Market Prospects: The launch of the IV Verify system reflects Baxter's ongoing commitment to advancing safe infusion practices, which is expected to drive growth in the company's market share within the healthcare technology sector, further solidifying its position as an innovation leader.
Newsfilter
1.0
03-25Newsfilter
Baxter's 2026 Annual Stockholders Meeting Details
  • Meeting Format: Baxter International Inc. will host its Annual Stockholders Meeting virtually on May 5, 2026, starting at 9 a.m. Central Time, with online access beginning at 8:45 a.m., ensuring a safe and convenient experience for all stockholders and employees.
  • Voting Arrangements: All stockholders are encouraged to vote their shares prior to the meeting using methods described in the proxy materials, while those who have not voted can do so electronically during the meeting, ensuring their voting rights are fully protected.
  • Question Submission: Stockholders can submit questions both before and during the meeting, with pre-meeting questions accepted from April 21 to May 4, 2026, and live questions allowed during the meeting, ensuring timely responses to stockholder concerns.
  • Guest Participation: Guests wishing to attend in listen-only mode can access the meeting via the website but will not have the ability to ask questions or vote, facilitating a smooth meeting process while still allowing stockholders to engage.
PRnewswire
7.5
03-25PRnewswire
Baxter Foundation's Major Investment in Therapy Animal Programs
  • Partnership Announcement: The Baxter Foundation collaborates with Pet Partners to promote therapy animal programs in U.S. healthcare settings, aiming to reach 100,000 patients and healthcare professionals within two years, thereby enhancing healthcare system resilience.
  • Pilot Program Launch: The initiative will begin in key regions such as Northern California, Upstate New York, and Greater Chicago, focusing on providing resources and training to help more healthcare facilities integrate animal therapy, addressing stress for healthcare workers and emotional challenges for patients.
  • Therapeutic Benefits: Research indicates that therapy animals can significantly lower pain ratings and reduce anxiety and depression in patients, while even brief five-minute visits from therapy dogs have been shown to alleviate stress for healthcare workers, highlighting the healing power of the human-animal bond.
  • Social Impact: This investment not only increases access to therapy animals but also enhances the mental health of healthcare workers and improves patient treatment experiences, demonstrating the Baxter Foundation's commitment to social responsibility.
NASDAQ.COM
2.0
03-24NASDAQ.COM
BAX vs CTRA Stock Performance Comparison
  • Price Dynamics: BAX is currently trading down approximately 0.1%, indicating a cautious market sentiment that may impact investor confidence and lead to capital outflows.
  • Strong CTRA Performance: In contrast, CTRA's stock is up about 3.3%, suggesting optimistic market expectations regarding its future growth potential, which may attract more investor interest.
  • Market Sentiment Analysis: The slight decline in BAX juxtaposed with CTRA's rise highlights differing risk assessments and market confidence among investors, potentially influencing future investment decisions.
  • Investor Focus: As the market compares the performances of BAX and CTRA, investors may reassess their portfolios to optimize returns and manage risks effectively.
moomoo
7.0
03-24moomoo
BAXTER - IFOSFAMIDE SUPPLY CONSTRAINTS EXPECTED TO GRADUALLY RESOLVE BY 2026
  • Limited Supply of IFOs: There is a restricted availability of IFOs (presumably a product or resource) currently affecting the market.

  • Gradual Improvement Expected: The situation is anticipated to improve gradually by the year 2026.

NASDAQ.COM
5.0
03-16NASDAQ.COM
Baxter CFO Joel Grade Departs for Family Reasons
  • Executive Departure: Baxter International announced the departure of CFO Joel Grade for family reasons, although he will remain in an advisory role until April 30, 2026, which may impact the company's financial decision-making and strategic direction.
  • Interim Appointment: Anita Zielinski has been appointed as interim CFO effective immediately; she has been with Baxter since 2025 as senior vice president and chief accounting officer, and her extensive experience in foodservice is expected to help maintain financial stability.
  • Financial Outlook Reaffirmed: Baxter reiterated its full-year 2026 financial outlook, demonstrating confidence in future performance during this executive transition, aimed at bolstering investor trust in the company.
  • Background and Experience: Zielinski previously served as senior vice president and CFO at Sysco and spent over 20 years at Ernst & Young, providing her with a robust financial management background that will aid the company in maintaining operational efficiency during the transition.
Wall Street analysts forecast BAX stock price to rise
8 Analyst Rating
Wall Street analysts forecast BAX stock price to rise
2 Buy
5 Hold
1 Sell
Hold
Current: 0.000
sliders
Low
15.00
Averages
22.13
High
30.00
Current: 0.000
sliders
Low
15.00
Averages
22.13
High
30.00
Citi
Neutral
downgrade
$21 -> $19
AI Analysis
2026-03-11
Reason
Citi
Price Target
$21 -> $19
AI Analysis
2026-03-11
downgrade
Neutral
Reason
Citi lowered the firm's price target on Baxter to $19 from $21 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical technology group post the Q4 reports. Sector fundamentals remain "healthy" despite the recent volatility, the analyst tells investors in a research note. Citi's top picks are iRhythm and Medtronic.
Goldman Sachs
Neutral
downgrade
$21 -> $17
2026-02-17
Reason
Goldman Sachs
Price Target
$21 -> $17
2026-02-17
downgrade
Neutral
Reason
Goldman Sachs lowered the firm's price target on Baxter to $17 from $21 and keeps a Neutral rating on the shares. The company's results and 2026 outlook generally fell short of estimates as margin pressures and higher non-operating items drove 2026 EPS guidance mid-point 16% below pre-Q4 consensus, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for BAX
Unlock Now

Valuation Metrics

The current forward P/E ratio for Baxter International Inc (BAX.N) is 8.41, compared to its 5-year average forward P/E of 15.06. For a more detailed relative valuation and DCF analysis to assess Baxter International Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
15.06
Current PE
8.41
Overvalued PE
19.19
Undervalued PE
10.93

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
12.37
Current EV/EBITDA
21.05
Overvalued EV/EBITDA
15.52
Undervalued EV/EBITDA
9.22

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
1.73
Current PS
0.70
Overvalued PS
2.44
Undervalued PS
1.01

Financials

AI Analysis
Annual
Quarterly

Related Community Screener

which stocks are bearish
Intellectia · 19 candidates
List Exchange: XNYS, XNAS, XASEMoving Average Relationship: PriceBelowMA20, PriceBelowMA200Month Price Change Pct: <= $-18.00Is Index Component: GSPCMacd: negative
Ticker
Name
Market Cap$
top bottom
LUV logo
LUV
Southwest Airlines Co
20.20B
ULTA logo
ULTA
Ulta Beauty Inc
23.20B
CCL logo
CCL
Carnival Corp
34.68B
IP logo
IP
International Paper Co
19.80B
CPB logo
CPB
Campbell's Co
6.43B
BF.B logo
BF.B
Brown-Forman Corp
10.62B
no which two coins under .01
Intellectia · 347 candidates
Turnover 24h: >= 0Price: $0.00 - $0.01Relative Vol: >= 0Dollar Volume 24h: >= 0
Ticker
Name
Market Cap$
top bottom
PEPE logo
PEPE
Pepe
1.65B
G logo
G
Gravity
56.10M
PUMP logo
PUMP
Pump.fun
716.00M
BONK logo
BONK
Bonk
579.97M
PENGU logo
PENGU
Pudgy Penguins
498.58M
SHIB logo
SHIB
Shiba Inu
3.66B
stocks to short
Intellectia · 43 candidates
Market Cap: >= 5.00BNet Margin: <= -5.00Rsi Category: overbought, moderateMoving Average Relationship: PriceBelowMA200Monthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
SNOW logo
SNOW
Snowflake Inc
60.65B
COIN logo
COIN
Coinbase Global Inc
51.03B
MSTR logo
MSTR
Strategy Inc
45.84B
CRWV logo
CRWV
CoreWeave Inc
41.98B
RBLX logo
RBLX
Roblox Corp
39.90B
TTWO logo
TTWO
Take-Two Interactive Software Inc
38.74B
what's a good day trade today
Intellectia · 119 candidates
Price: $5.00 - $80.00Rsi Category: moderatePrice Change Pct: $4.00 - $20.00Relative Vol: >= 1.80List Exchange: XNYS, XNAS, XASEMonthly Average Dollar Volume: >= 2,000,000
Ticker
Name
Market Cap$
top bottom
AAL logo
AAL
American Airlines Group Inc
9.40B
SMCI logo
SMCI
Super Micro Computer Inc
17.40B
CMCSA logo
CMCSA
Comcast Corp
107.79B
HPQ logo
HPQ
HP Inc
17.23B
GPK logo
GPK
Graphic Packaging Holding Co
3.60B
JBLU logo
JBLU
JetBlue Airways Corp
2.05B
health care
Intellectia · 10 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Sector: Healthcare, Healthcare Services & EquipmentPe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
UNH logo
UNH
UnitedHealth Group Inc
315.01B
NVS logo
NVS
Novartis AG
278.44B
NVO logo
NVO
Novo Nordisk A/S
263.42B
GILD logo
GILD
Gilead Sciences Inc
160.18B
PFE logo
PFE
Pfizer Inc
147.20B
ELV logo
ELV
Elevance Health Inc
82.20B
what healthcare stocks should i buy
Intellectia · 10 candidates
Market Cap: >= 10.00BDividend Yield Ttm: >= 2Sector: Healthcare, Healthcare Services & EquipmentPe Ttm: <= 20
Ticker
Name
Market Cap$
top bottom
UNH logo
UNH
UnitedHealth Group Inc
315.01B
NVS logo
NVS
Novartis AG
278.44B
NVO logo
NVO
Novo Nordisk A/S
263.42B
GILD logo
GILD
Gilead Sciences Inc
160.18B
PFE logo
PFE
Pfizer Inc
147.20B
ELV logo
ELV
Elevance Health Inc
82.20B
find similar stocks of hims and hers
Intellectia · 208 candidates
Market Cap: 300.00M - 15.00BPs Ratio: <= 15.00Is Optionable: TrueAnnual Revenue Yoy Growth: >= 0.0%
Ticker
Name
Market Cap$
top bottom
GH logo
GH
Guardant Health Inc
14.98B
ICLR logo
ICLR
ICON PLC
14.12B
PEN logo
PEN
Penumbra Inc
14.03B
SOLV logo
SOLV
Solventum Corp
13.94B
SNN logo
SNN
Smith & Nephew PLC
13.91B
NBIX logo
NBIX
Neurocrine Biosciences Inc
13.50B
best medical 3 stocks to buy under $20
Intellectia · 22 candidates
Market Cap: >= 500.00MPrice: <= $20.00Beta: LowRiskWeekly Average Turnover: >= 1,000,000
Ticker
Name
Market Cap$
top bottom
TAK logo
TAK
Takeda Pharmaceutical Co Ltd
51.17B
HLN logo
HLN
Haleon PLC
45.60B
KVUE logo
KVUE
Kenvue Inc
33.30B
VTRS logo
VTRS
Viatris Inc
15.03B
RDY logo
RDY
Dr Reddy's Laboratories Ltd
11.06B
BAX logo
BAX
Baxter International Inc
10.13B

Whales Holding BAX

T
Thompson, Siegel & Walmsley LLC
Holding
BAX
+0.01%
3M Return
A
ARGA Investment Management, LLC
Holding
BAX
-0.35%
3M Return
G
Greenhaven Associates Inc
Holding
BAX
-6.31%
3M Return
P
Pzena Investment Management, Inc.
Holding
BAX
-12.73%
3M Return
M
MIV Asset Management AG
Holding
BAX
-15.80%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Baxter International Inc (BAX) stock price today?

The current price of BAX is 16.6 USD — it has increased 5.06

What is Baxter International Inc (BAX)'s business?

Baxter International Inc. is a global medtech company. Its segments include Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals. The Medical Products and Therapies segment includes sales of its sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant, and adhesion prevention products. The Healthcare Systems and Technologies segment includes sales of its connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices, and advanced equipment for the surgical space, including operating room integration technologies, precision positioning devices, and other accessories. The Pharmaceuticals segment includes sales of specialty injectable pharmaceuticals, inhaled anesthesia, and drug compounding. It provides a portfolio of diagnostic, critical care, nutrition, hospital and surgical products.

What is the price predicton of BAX Stock?

Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is22.13 USD with a low forecast of 15.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Baxter International Inc (BAX)'s revenue for the last quarter?

Baxter International Inc revenue for the last quarter amounts to 2.97B USD, increased 8.03

What is Baxter International Inc (BAX)'s earnings per share (EPS) for the last quarter?

Baxter International Inc. EPS for the last quarter amounts to -2.20 USD, increased 120.00

How many employees does Baxter International Inc (BAX). have?

Baxter International Inc (BAX) has 37500 emplpoyees as of March 31 2026.

What is Baxter International Inc (BAX) market cap?

Today BAX has the market capitalization of 8.16B USD.